Impact on Survival with Immunotherapy and Evaluation of Biomarkers in Peruvian Patients with Advanced Melanoma

Guillermo Valencia, Katia Roque, Patricia Rioja, José Andrés Huamán, Valeria Colomo, Jorge Sánchez, Cindy Calle, Raúl Mantilla, Zaida Morante, Hugo Fuentes, Tatiana Vidaurre, Silvia Neciosup, Ramon Andrade De Mello, Henry L. Gómez, Amaya B. Fernández-Díaz, Alfonso Berrocal, Carlos Castaneda

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Advanced malignant melanoma is a very aggressive disease, historically with poor prognosis before the new advances with immunotherapy and targeted therapies that have changed the standard of care, especially in cutaneous melanoma. Peru has aggressive features such as higher rates of acral lentiginous melanoma (ALM) subtype with historically shorter survival. Methods: This study describes Peruvian patients with advanced melanoma treated with immunotherapy (nivolumab) in two oncological institutions (public and private), including the discussion of the impact on overall survival (OS) divided by subtype (with incidence in ALM histology) and potential biomarkers that could be related to prognosis. Results: We found that immunotherapy is safe, and improves progression-free survival (PFS), OS and objective response rate (ORR) in our patients, with lower benefit in ALM histology. No prognostic blood inflammatory biomarkers were detected. Discussion: There is very limited data of Peruvian patients with metastatic melanoma treated with immunotherapy, especially the outcomes in ALM histology. Our goal is to share an example of the impact of immunotherapy in a Latin American (LATAM) population considered as an unsatisfied group with an enormous need of novel treatments and biomarkers.

Original languageEnglish
Pages (from-to)871-886
Number of pages16
JournalOncoTargets and Therapy
Volume17
DOIs
StatePublished - 2024

Keywords

  • Peru
  • advanced melanoma
  • biomarkers
  • immunotherapy
  • overall survival

Fingerprint

Dive into the research topics of 'Impact on Survival with Immunotherapy and Evaluation of Biomarkers in Peruvian Patients with Advanced Melanoma'. Together they form a unique fingerprint.

Cite this